Comments

Rani Therapeutics Hldgs

RANINASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$3.50
-0.45-11.39%
Pre-Market: Jul 10, 9:17 AM EDT
15 minutes delayed
Rani Therapeutics Hldgs (RANI) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$24.00
Lowest Price Target1
$8.00
Consensus Price Target1
$15.55

want to know what
the Bulls & Bears Say?

Rani Therapeutics Hldgs (NASDAQ:RANI) Stock, Analyst Ratings, Price Targets, Forecasts

Rani Therapeutics Holdings Inc has a consensus price target of $15.55 based on the ratings of 11 analysts. The high is $24 issued by Stifel on August 24, 2021. The low is $8 issued by Wedbush on February 6, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Maxim Group, and Rodman & Renshaw on June 25, 2024, June 14, 2024, and June 13, 2024, respectively. With an average price target of $12.67 between HC Wainwright & Co., Maxim Group, and Rodman & Renshaw, there's an implied 220.68% upside for Rani Therapeutics Holdings Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Feb
0
0
0
0
Mar
0
0
0
0
May
0
0
0
0
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.1
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Maxim Group
Rodman & Renshaw
BTIG
Canaccord Genuity

1calculated from analyst ratings

Analyst Ratings for Rani Therapeutics Hldgs

Buy NowGet Alert
06/25/2024Buy Now229.11%HC Wainwright & Co.
Mitchell Kapoor
$13 → $13ReiteratesBuy → BuyGet Alert
06/14/2024Buy Now279.75%Maxim Group— → $15Initiates → BuyGet Alert
06/13/2024Buy Now153.16%Rodman & Renshaw
Brandon Folkes
 → $10Initiates → BuyGet Alert
05/09/2024Buy Now254.43%BTIG
Robert Hazlett
$7 → $14MaintainsBuyGet Alert
05/07/2024Buy Now229.11%HC Wainwright & Co.
Mitchell Kapoor
$12 → $13MaintainsBuyGet Alert
03/27/2024Buy Now127.85%Canaccord Genuity
Edward Nash
$21 → $9MaintainsBuyGet Alert
03/25/2024Buy Now203.8%HC Wainwright & Co.
Mitchell Kapoor
$16 → $12MaintainsBuyGet Alert
02/06/2024Buy Now102.53%Wedbush
Andreas Argyrides
 → $8ReiteratesOutperform → OutperformGet Alert
11/09/2023Buy Now305.06%HC Wainwright & Co.
Mitchell Kapoor
$20 → $16MaintainsBuyGet Alert
09/20/2023Buy Now406.33%HC Wainwright & Co.
Mitchell Kapoor
 → $20ReiteratesBuy → BuyGet Alert
09/08/2023Buy Now406.33%HC Wainwright & Co.
Mitchell Kapoor
 → $20ReiteratesBuy → BuyGet Alert
08/21/2023Buy Now330.38%B of A Securities
Geoff Meacham
$19 → $17MaintainsBuyGet Alert
08/17/2023Buy Now406.33%Wedbush
Andreas Argyrides
 → $20ReiteratesOutperform → OutperformGet Alert
08/14/2023Buy Now406.33%HC Wainwright & Co.
Mitchell Kapoor
$22 → $20MaintainsBuyGet Alert
06/06/2023Buy Now456.96%HC Wainwright & Co.
Mitchell Kapoor
 → $22ReiteratesBuy → BuyGet Alert
05/11/2023Buy Now456.96%HC Wainwright & Co.
Mitchell Kapoor
 → $22ReiteratesBuy → BuyGet Alert
03/23/2023Buy Now456.96%HC Wainwright & Co.
Mitchell Kapoor
 → $22Reiterates → BuyGet Alert
10/11/2022Buy Now279.75%UBS
Ashwani Verma
 → $15Initiates → BuyGet Alert
07/27/2022Buy Now456.96%HC Wainwright & Co.
Mitchell Kapoor
 → $22Initiates → BuyGet Alert
06/13/2022Buy Now608.86%Wedbush
Andreas Argyrides
 → $28Initiates → OutperformGet Alert
08/25/2021Buy Now507.59%BTIG
Robert Hazlett
—Initiates → BuyGet Alert
08/24/2021Buy Now482.28%B of A Securities——Initiates → BuyGet Alert
08/24/2021Buy Now482.28%Cantor Fitzgerald
Brandon Folkes
—Initiates → OverweightGet Alert
08/24/2021Buy Now507.59%Stifel
Annabel Samimy
—Initiates → BuyGet Alert

FAQ

Q

What is the target price for Rani Therapeutics Hldgs (RANI) stock?

A

The latest price target for Rani Therapeutics Hldgs (NASDAQ:RANI) was reported by HC Wainwright & Co. on June 25, 2024. The analyst firm set a price target for $13.00 expecting RANI to rise to within 12 months (a possible 271.43% upside). 14 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Rani Therapeutics Hldgs (RANI)?

A

The latest analyst rating for Rani Therapeutics Hldgs (NASDAQ:RANI) was provided by HC Wainwright & Co., and Rani Therapeutics Hldgs reiterated their buy rating.

Q

When was the last upgrade for Rani Therapeutics Hldgs (RANI)?

A

There is no last upgrade for Rani Therapeutics Hldgs

Q

When was the last downgrade for Rani Therapeutics Hldgs (RANI)?

A

There is no last downgrade for Rani Therapeutics Hldgs.

Q

When is the next analyst rating going to be posted or updated for Rani Therapeutics Hldgs (RANI)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rani Therapeutics Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rani Therapeutics Hldgs was filed on June 25, 2024 so you should expect the next rating to be made available sometime around June 25, 2025.

Q

Is the Analyst Rating Rani Therapeutics Hldgs (RANI) correct?

A

While ratings are subjective and will change, the latest Rani Therapeutics Hldgs (RANI) rating was a reiterated with a price target of $13.00 to $13.00. The current price Rani Therapeutics Hldgs (RANI) is trading at is $3.50, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch